AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of SEK 2.08 trillion. The enterprise value is 2.34 trillion.

Market Cap	2.08T
Enterprise Value	2.34T

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	Feb 20, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.06%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 26.67.

PE Ratio	26.67
Forward PE	n/a
PS Ratio	3.47
PB Ratio	4.59
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.56, with an EV/FCF ratio of 21.25.

EV / Earnings	30.02
EV / Sales	4.15
EV / EBITDA	12.56
EV / EBIT	17.41
EV / FCF	21.25

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.75.

Current Ratio	0.93
Quick Ratio	0.67
Debt / Equity	0.75
Debt / EBITDA	1.70
Debt / FCF	3.07
Interest Coverage	9.22

Financial Efficiency

Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 11.53%.

Return on Equity (ROE)	17.59%
Return on Assets (ROA)	7.88%
Return on Invested Capital (ROIC)	11.53%
Return on Capital Employed (ROCE)	16.97%
Revenue Per Employee	6.35M
Profits Per Employee	825,649
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.84% in the last 52 weeks. The beta is 0.25, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	-10.84%
50-Day Moving Average	1,515.82
200-Day Moving Average	1,565.49
Relative Strength Index (RSI)	40.10
Average Volume (20 Days)	475,980

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of SEK 598.44 billion and earned 77.86 billion in profits. Earnings per share was 49.80.

Revenue	598.44B
Gross Profit	491.78B
Operating Income	143.09B
Pretax Income	96.19B
Net Income	77.86B
EBITDA	194.42B
EBIT	143.09B
Earnings Per Share (EPS)	49.80

Full Income Statement

Balance Sheet

The company has 61.15 billion in cash and 337.11 billion in debt, giving a net cash position of -275.96 billion.

Cash & Cash Equivalents	61.15B
Total Debt	337.11B
Net Cash	-275.96B
Net Cash Per Share	n/a
Equity (Book Value)	452.33B
Book Value Per Share	291.12
Working Capital	-22.57B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 131.27 billion and capital expenditures -21.29 billion, giving a free cash flow of 109.98 billion.

Operating Cash Flow	131.27B
Capital Expenditures	-21.29B
Free Cash Flow	109.98B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.18%, with operating and profit margins of 23.91% and 13.01%.

Gross Margin	82.18%
Operating Margin	23.91%
Pretax Margin	16.07%
Profit Margin	13.01%
EBITDA Margin	32.49%
EBIT Margin	23.91%
FCF Margin	18.38%

Dividends & Yields

This stock pays an annual dividend of 33.75, which amounts to a dividend yield of 2.60%.

Dividend Per Share	33.75
Dividend Yield	2.60%
Dividend Growth (YoY)	11.42%
Years of Dividend Growth	3
Payout Ratio	65.80%
Buyback Yield	-0.06%
Shareholder Yield	2.53%
Earnings Yield	3.75%
FCF Yield	5.30%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.15.

Altman Z-Score	3.15
Piotroski F-Score	n/a